Transcatheter Interventions for Atrioventricular Dysfunction in Patients with Adult Congenital Heart Disease: An International Case Series.
ACHD
atrioventricular valve
transcatheter
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Jan 2023
09 Jan 2023
Historique:
received:
12
12
2022
revised:
28
12
2022
accepted:
05
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
A substantial proportion of patients with adult congenital heart disease (ACHD) suffer from worsening valvular dysfunction in adulthood. Transcatheter valve interventions can offer a therapeutic alternative to surgery for those at high surgical risk. There is emerging but limited data on transcatheter interventions for atrioventricular (AV) valve dysfunction in patients with ACHD. We compiled an international collaborative multi-center registry focusing on adult patients with congenital heart disease undergoing transcatheter AV valve interventions (repair or replacement). Included were patients from three international centers who underwent procedures between 2016 and 2022. Demographic, clinical, and procedural data were compiled. Nine patients with ACHD underwent AV valve interventions. The median age was 48 years (IQR (37; 56), 55% women). At baseline, seven patients (78%) were in NYHA functional class III and two (22%) were in NYHA functional class II. The diagnosis of ACHD varied. Three valve interventions were performed on the subpulmonary AV valve and six on the systemic AV valve. The primary valvular pathology was regurgitation (six patients, 78%). Five procedures were valve-in-valve interventions, and four procedures were transcatheter edge-to-edge repair procedures. There were no major complications or peri-procedural complications or peri-procedural mortality. One patient developed a suspected non-obstructive thrombus on the valve that was medically treated. One patient did not improve clinically following the procedure and underwent a heart transplant, one patient died 6 months following the procedure due to a cardiovascular implantable electronic device infection. At one year, six patients were in NYHA functional class I, and one patient was in NYHA functional class III. In conclusion, transcatheter AV heart valve interventions are feasible and safe procedures in carefully selected ACHD patients. These procedures can offer an effective treatment option in these younger patients with high surgical risk.
Identifiants
pubmed: 36675450
pii: jcm12020521
doi: 10.3390/jcm12020521
pmc: PMC9864755
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cardiol. 2020 Jan 1;298:83-84
pubmed: 31629565
Circulation. 2021 Mar 9;143(10):1043-1061
pubmed: 33683945
Cardiovasc Diagn Ther. 2021 Jun;11(3):818-839
pubmed: 34295708
Circulation. 2019 Apr 2;139(14):e698-e800
pubmed: 30586767
EuroIntervention. 2021 Oct 20;17(9):744-746
pubmed: 33528360
Circulation. 2010 Nov 30;122(22):2264-72
pubmed: 21098444
Am J Cardiol. 2018 Jan 15;121(2):262-268
pubmed: 29153244
Cardiol Young. 2010 Dec;20 Suppl 3:143-8
pubmed: 21087572
Catheter Cardiovasc Interv. 2021 Feb 15;97(3):542-548
pubmed: 32898313
Eur Heart J. 2021 Feb 11;42(6):563-645
pubmed: 32860028
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165